A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Document Type
Journal Article
Publication Date
2-28-2017
Journal
Neuro-Oncology
Volume
19
Issue
8
Inclusive Pages
1135-1144
DOI
10.1093/neuonc/now282
APA Citation
Banerjee, A., Jakacki, R., Onar-Thomas, A., Wu, S., Nicolaides, T., Young Poussaint, T., Fangusaro, J., Phillips, J., Perry, A., Turner, D., Prados, M., Packer, R., Qaddoumi, I., Gururangan, S., Pollack, I., Goldman, S., Doyle, L., Stewart, C., Boyett, J., Kun, L., & Fouladi, M. (2017). A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.. Neuro-Oncology, 19 (8). http://dx.doi.org/10.1093/neuonc/now282
Peer Reviewed
1
